- Home
- PERI vs RCKT Comparison
PERI vs RCKT Comparison
Compare PERI & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PERI | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 394.2M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PERI | RCKT |
|---|---|---|
| Price | $8.72 | $2.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $13.00 | $8.58 |
| AVG Volume (30 Days) | 237.2K | ★ 2.1M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.37 |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $10.33 | $915.60 |
| P/E Ratio | ★ N/A | $3.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.63 | $2.18 |
| 52 Week High | $11.27 | $5.45 |
Technical Indicators
Market Signals| Indicator | PERI | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 48.09 | 29.92 |
| Support Level | $8.28 | N/A |
| Resistance Level | $9.70 | $3.70 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 51.91 | 5.00 |
Price Performance
Historical ComparisonAbout PERI Perion Network Ltd.
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.